Avantor Finally Grows Again — and Gives the Cycle a Bigger Share of the Credit
First positive organic print in years, a raised guide and a 77% 90-day rally — but pricing still lags inflation, Europe is on a 'static' assumption, and management quietly diluted its self-help story.
AVTR · Earnings Call · 2026-10-28
The turn is real, and both halves of the company showed up
Avantor reported third-quarter revenue of $1.698 billion on October 28 — up 5.2% organically and 4.6% reported — the first positive organic growth print in a very long time, and the first quarter in memory in which both segments were green simultaneously. VWR, the distribution engine that is roughly 70% of revenue, accelerated to 5.8% organic growth on $1.23 billion. Bioscience and Medtech Products, which had been the sick patient, delivered 3.6% organic growth on $465 million. “Our third quarter results make a return to organics revenue growth for Avantor. This is an important milestone on our revival journey.” — Emmanuel Ligner, President and Chief Executive Officer · 2026-10-28 The mix of drivers is what you want to see in a genuine turn rather than a comp-driven one. process chemicals grew high-single digits on both orders and sales year-to-date; NuSil grew at a low teens rate on a healthy order book; the CEO noted a third consecutive quarter of positive book-to-bill in BMP with lead times of three to six months. The company's own framing of the demand backdrop is unambiguous — stronger end markets in the Americas and Asia, with green shoots in North American higher education and early-stage biotech funding. Add a raise in full-year organic revenue (to 0.75-1.25%), adjusted EPS ($0.81-$0.83) and free cash flow ($520-550 million), and the quarter reads as a company finally converting growth acceleration into guidance.The part of the story that got quieter
Here is where a careful reader should slow down. A quarter ago, management attributed the VWR recovery mostly to itself: “more than half of the growth that we deliberated in Q2 comes from deliberated action that we're taking.” — Emmanuel Ligner, President and Chief Executive Officer · 2026-07-29 This quarter, the split moved: “I think we share about a half. And when we think about the half about the action we have taken.” — Emmanuel Ligner, President and Chief Executive Officer · 2026-10-28 Half self-help, half market. That is not a confession — it is arithmetic — but it materially changes what a buyer of the equity is underwriting. If roughly half of VWR's 5.8% came from an improving return to organic revenue cycle rather than the company's own growth investments, then the upside is more levered to a life-science tools recovery than to a proprietary turnaround — and equally more exposed if that recovery stalls. Margins tell the same story with less polish. Adjusted EBITDA margin of 15.1% expanded only sequentially; second-quarter gross margin of 31.7%, down 1.2 points year-over-year reflects mix: VWR grew faster than BMP and within VWR the growth skewed to lower-margin categories. The offset — pricing — is still behind the curve.Chasing, in a quarter where Middle East conflict is inflating freight and critical materials. cost discipline and EBITDA margin expansion are real but incremental, and the CFO would only commit to margins expanding "modestly" from Q3 to Q4 — while explicitly declining to guide segments. And geography is a free option, not a forecast. On Europe: “In our guide, we are looking at a static call. So any recovery will give us a tailwind.” — Emmanuel Ligner, President and Chief Executive Officer · 2026-10-28 Fair framing, but it means the raised guide embeds no European improvement — and Europe is where Avantor has the number-one distribution position.Our data shows that our pricing is between 1% and 2% in the year-to-date... That is less than we have seen from inflation. Right? So we are chasing it a little bit.
The tape has already voted — hard
Avantor's stock is up 77% in the last 90 trading days, closing within 3.5% of its October 23 high of $17.29. That is an outlier return for an $11.3 billion medical-supplies name, and it happened before this print. The re-rating is understandable against the multiple: Price to revenue of about 1.0x versus 3.5x at the 2021 peak, with the stock still 62% below its $44.01 high of September 2021. Cheap plus a turn equals the rally. But note the sequencing tension: the tape moved first, the numbers confirmed second, and the guide only rose by the magnitude of the third-quarter beat. Q4 organic growth is guided to 2.5-4.5%, implying a deceleration from 5.2%, with BMP flat to slightly positive against a roughly 400 basis point comparison headwind. The basis point headwind vocabulary that dominated 2026 — serum, electronic materials, discrete ordering patterns — is thinning, but it has not vanished, and it is now doing the work of explaining why momentum looks better than the guide.December 8 is the real catalyst
The financial architecture is improving. Net debt fell $173 million in the quarter to $3.235 billion, adjusted net leverage dropped to 3.1x from 3.3x, and management reaffirmed sub-3x by year-end. Effective net cash of roughly negative $3.4 billion is a legacy of the 2021 acquisition era, and every turn of deleveraging buys back strategic optionality. Interest coverage of 3.1x is serviceable, not comfortable. Free cash flow is the genuine asset: $125 million of free cash flow less stock comp in the June quarter, $169 million ex-restructuring in Q3, and a cash generation profile management rightly calls a key strength. The open questions land on December 8 at Investor Day: a long-term margin framework (will VWR ever return to its historical 10-11% operating range?), a 2027 guide the CEO deferred — “we will talk about much more about our guide and what we think for 2027 in those detailed right, during our Q4 earning course in February.” — Emmanuel Ligner, President and Chief Executive Officer · 2026-10-28 — and the credibility test of a freshly completed leadership team, with CFO Todd Garner five weeks in and a new CIO arriving from Danaher. The prior promise stands as the benchmark:One thing the call did not do is claim an AI edge. Asked directly, Emmanuel Ligner offered consensus rather than content: “There is definitely a consensus in the industry about AI being a tailwind for us... any increase of productivity in the money spent by pharma in developing new molecules is good for us.” — Emmanuel Ligner, President and Chief Executive Officer · 2026-10-28 That is honest, and it is the correct answer for a reagent-and-distribution business — but against a global tape where AI-adjacent themes dominate both advancers and decliners, Avantor is a derivative play on pharma R&D budgets, not a participant. Its real moat language is duller and more durable: security of supply, redundancy, and multi-region manufacturing. The quarter justifies the rally. The next 20% has to be earned by margins, not by comps.2027, every day, every month, the last 90 days, my confidence is increasing, and I'm confident and optimistic that 2027 will be a growth year.